Navigation Links
Pfenex Inc. Establishes Reagent Protein Distribution Agreement With Cedarlane Corporation
Date:8/24/2010

SAN DIEGO, Aug. 24 /PRNewswire/ -- Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b. New products which are developed by Pfenex will be added to the Cedarlane catalogue upon launch.

"We are pleased to establish this distribution relationship with Cedarlane," stated Patrick K. Lucy, Vice President, Business Development at Pfenex Inc. "Leveraging the Pfenex Expression Technology™ platform, we are now producing and making available complex reagent proteins to meet the needs of the biotech R&D and clinical development community. As Pfenex grows its reagent proteins business, we welcome the opportunity to work with world class distributors such as Cedarlane to enable placing Pfenex products in the hands of life science researchers around the world."

"CEDARLANE is proud to add Pfenex Inc. products to its extensive portfolio," said John Course, CEDARLANE Vice President. "Canadian scientists have an even greater opportunity to consolidate their ordering from a long list of high-quality suppliers of scientific reagents." Key components of the CEDARLANE mission are to provide quality products, assure the highest in customer satisfaction and respond to the dynamic needs of every research community.

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About CEDARLANE

In business since 1957 and incorporated in 1975, CEDARLANE is a 100% Canadian Corporation and a leading supplier of research reagents in North America and worldwide. The company is ISO 9001 accredited and ISO 13485 certified.

www.pfenex.com

www.cedarlanelabs.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
2. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
3. Mach 7 Technologies Establishes New Headquarters in Burlington, VT
4. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
5. BD Establishes $1.2 Million Fund for Haiti Earthquake Relief Efforts
6. FUJIFILM Establishes Medical Informatics Organization
7. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
8. Pharmaxis Establishes Named Patient Program for Bronchitol
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
11. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Alkermes PLC ... AMAG ), IDEXX Laboratories Inc. (NASDAQ: IDXX ... Learn more about these stocks by accessing their free trade ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... To ... infrastructure. Most providers, however, are unsure how to move forward, given the need ... define a path forward tailored to an organization’s specific needs. , PYA Principal ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... SpiritQuest Sedona ... heart of West Sedona, surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and ... partner properties – the Lodge at Sedona as well as the Sedona Rouge, both ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... An ... may expose a possible link between head and neck cancer in individuals with unhealthy ... the study were evaluated based on whether they had gum disease, brushed their teeth ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
Breaking Medicine News(10 mins):